Feng Chi Biotech Corp.

TPEX:6744 Stock Report

Market Cap: NT$303.4m

Feng Chi Biotech Past Earnings Performance

Past criteria checks 1/6

Feng Chi Biotech has been growing earnings at an average annual rate of 2.5%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 1% per year. Feng Chi Biotech's return on equity is 8.3%, and it has net margins of 11.1%.

Key information

2.5%

Earnings growth rate

1.6%

EPS growth rate

Healthcare Industry Growth9.1%
Revenue growth rate1.0%
Return on equity8.3%
Net Margin11.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Feng Chi Biotech Corp. (GTSM:6744) Is Yielding 3.3% - But Is It A Buy?

Jan 20
Feng Chi Biotech Corp. (GTSM:6744) Is Yielding 3.3% - But Is It A Buy?

Is Weakness In Feng Chi Biotech Corp. (GTSM:6744) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Nov 25
Is Weakness In Feng Chi Biotech Corp. (GTSM:6744) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Revenue & Expenses Breakdown

How Feng Chi Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6744 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24173194613
31 Mar 24177214513
31 Dec 23181234312
30 Sep 23182234312
30 Jun 23184244312
31 Mar 23189244412
31 Dec 22193254412
30 Sep 22190234413
30 Jun 22187214414
31 Mar 22185224514
31 Dec 21183234514
30 Sep 21181254613
30 Jun 21179264712
31 Mar 21179264612
31 Dec 20179254512
30 Sep 20181254412
30 Jun 20182244212
31 Mar 20178214113
31 Dec 19174173913
30 Sep 19171173913
30 Jun 19167163913
31 Mar 19158173814
31 Dec 18148173714
31 Dec 1712513368
31 Dec 1614016415

Quality Earnings: 6744 has a high level of non-cash earnings.

Growing Profit Margin: 6744's current net profit margins (11.1%) are lower than last year (13.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6744's earnings have grown by 2.5% per year over the past 5 years.

Accelerating Growth: 6744's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6744 had negative earnings growth (-20%) over the past year, making it difficult to compare to the Healthcare industry average (7.3%).


Return on Equity

High ROE: 6744's Return on Equity (8.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 01:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Feng Chi Biotech Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution